Warts
Conditions
Brief summary
The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.
Interventions
DIAGNOSTIC_TESTendoplasmic reticulum Aminopeptidase 1 and 2
endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA
DIAGNOSTIC_TESTendoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA
endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA
Sponsors
Benha University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
• Patients who had a history of incomplete clearance or recurrence following two or more electrocautery sessions and four or more cryocautery treatments and intralesional bleomycin.
Exclusion criteria
* Patients with genital warts * Patients on systemic steroids or other immunosuppressive treatments * Immunocompromised individuals * Patients suffering from chronic systemic diseases * Pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SERUM LEVELS OF endoplasmic reticulum aminopeptidase 1 and 2 | ONE YEAR | using specific Commercial human ELISA kits |
Countries
Egypt
Outcome results
None listed